RELiZORB RELiZORB is a digestive enzyme cartridge designed to hydrolyze fats contained in enteral formulas. The Food and Drug Administration (FDA) has cleared RELiZORB (immobilized lipase) cartridge ...

WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced ...

WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced ...

Next-generation RELiZORB technology expands device utility to support more patients including many living with SBS and other rare diseases. "Tube-fed patients have a wide range of enteral nutrition ...

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a ...

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced that Massachusetts General Hospital (MGH) has enrolled ...

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced that the US Food and Drug Administration (FDA) has ...

Clinical data published in Nutrients highlights significant improvements in weight and body mass index (BMI) z-scores with use of RELiZORB WALTHAM, Mass., Jan. 23, 2026 /PRNewswire/ -- Alcresta ...

Alcresta has received de novo approval from the FDA to market Relizorb (immobilized lipase), a first-of-its kind digestive enzyme cartridge that breaks down fats in enteral tube feeding formula to ...

Next-generation RELiZORB technology expands device utility to support more patients including many living with SBS and other rare diseases. WALTHAM, Mass., Dec. 21, 2023 /PRNewswire/ -- Alcresta ...